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1: Introduction
1.1 Chemotherapy targeting the cytoskeleton
Since decades, the cytoskeleton is targeted in the chemotherapeutic treatment of cancer.
Drugs targeting microtubules have been used in the clinic since the early 60s and are the
most frequently applied class of anti cancer drugs [1, 2]. The functionality of microtubule
targeting drugs is attributed to the inhibition of mitosis as well as the induction of apop-
tosis, inhibition of angiogenesis and metastasis [3, 2]. Although a very ubiquitous protein
is targeted, the widespread use in the clinic reflects the pharmacological importance of mi-
crotubule targeting drugs. However, side effects affecting the nervous system and the de-
velopment of resistances constantly raise the need for new targets and strategies. Analogue
to microtubules, the cytoskeletal component actin is involved in pro-oncogenic processes
like cytokinesis as well as angiogenesis and metastasis. These parallels highlight the actin
cytoskeleton as an interesting target for cancer therapy.
1.2 Actin as a potential target
1.2.1 Advantages of actin targeting
Actin reveals several advantages as a target in cancer therapy. First of all, actin is the
most abundant protein through all eukaryotes and even bacteria show derivatives [4, 5, 6].
Through all those species, the structure of actin is highly conserved and actin interacts with
more than 100 other proteins requiring a stringent conserved structure. Due to this enor-
mous conservation, actin is very unlikely to mutate and develop resistances against thera-
pies. Second, cancer cells reveal differences in actin turnover compared to normal cells. So
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cancer cells show a higher value of unpolymerized actin compared to normal cells [7] and
during metastasis a higher actin turnover is required than for stationary cells which could
make them more vulnerable to actin binding substances compared to normal tissue. Third,
the more aggressive mesenchymal cells are more sensitive to actin targeting compounds
whereas more quiescent, epithelial like cells show higher sensitivity to microtubule binding
agents [8] revealing actin as the preferable target for mesenchymal cells.
Despite all these advantages, actin itself was not considered as a potential target during the
last decades. The reason therefore lies mostly in the very first in vivo studies. In 1985 the
actin binding compound Phalloidin was administered in vivo and referred to be too toxic
due to liver toxicity [9]. 1988, Scott and collegues tested Jasplakinolide in vivo and proposed
the subastance as too toxic for clinical application [10]. However, new actin binding sub-
stances with modified properties are still found and the combination with modern targeting
strategies could facilitate their use nowadays.
1.2.2 Actin structures and their cellular function
Structurally, the actin molecule is a 42 kDa, globular protein that forms microfilaments.
Actin monomers (G-actin) spontaneously polymerize into linear filaments (F-actin) with a
minimal nucleation seed of four monomers. Actin filaments are directed as all monomers
are oriented in the same direction leading to a so called barbed and a pointed end whereby
polymerization occurs predominantly at the barbed end (Figure 1.1 A). Actin polymers are
further processed via a high number of actin interacting proteins. So the polymerization
of actin is enhanced by the nucleation and elongation factor Formin. Existing filaments are
prevented from elongation e.g. by the barbed-end capping protein CapZ or can be refracted
by severing proteins like Gelsolin or Cofilin. Further, net like structures are facilitated by
Arp2/3 complex binding to existing filaments enabling the nucleation of new filaments in
an angle of 70◦ (Figure 1.1 B). The concerted action of all these proteins transforms linear
actin polymers in more complex structures, as there are: the contractile ring, lamellipodia or
stress fibers (Figure 1.1 C). These higher structures finally fulfill the actin dependent cellular
functions like cytokinesis, cellular protrusion and cellular contractility, respectively. [4, 11]
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Figure 1.1: Actin structures. A: Polymerization of actin. Actin polymerization requires
a minimum of four subunits for efficient polymerization. Polymerization is faster at
the barbed end (B) compared to the pointed end (P). B: Complex actin structures are
achieved by the interaction with actin binding proteins leading to capping, severing or
branching of actin fibers. C: Actin builds up the contractile ring in cytokinesis as well
as lamellipodia and stress fibers in migrating cells.
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1.3 Source for actin targeting: natural compounds
Many chemotherapeutics were inspired by compounds isolated from natural sources [12,
13]. In case of microtubules, even all therapeutically applied tubulin binding drugs are nat-
ural compounds or derivatives [2]. Interestingly, also for actin, nature has developed several
compounds binding and affecting actin filaments [14, 15]. So obviously, also nature has re-
garded the actin cytoskeleton as a rewarding target.
The actin binding compounds can be distinguished in two groups: first, F-actin stabilizing
and, second, F-actin destabilizing compounds. The most well known agents as F-actin stabi-
lizer are Phalloidin which was first isolated from ’Death cap’ mushroom Amanita phalloides
and Jasplakinolide from the marine sponge Jaspis johnstoni [16, 17]. As F-actin destabilizer
Cytochalasins, from fungea, and Latrunculin A from the Red Sea sponge Negombata mag-
nifica [18, 19] are the most prominent representatives. Further, the list can be elongated as
new compounds are still found.
1.4 Myxobacteria as pharmaceutical factory
An enormous source of pharmaceutically active compounds are myxobacteria. Myxobac-
teria belong to proteobacteria, reside mainly in soil [20, 21] and are characterized by the
formation of fruiting bodies when resources are rare [20]. For pharmacological develop-
ment, myxobacteria are attractive due to their rich metabolomic diversity enabling them
to produce a huge number of secondary metabolites structurally different from those from
other microbes [22, 23]. In fact, 40% of the myxobacterial compounds include novel chem-
ical structures [20]. Additionally, recent developments in the cultivation of myxobacteria
and the possibility of genetic engineering will further increase the possiblities for the iden-




1.5.1 Isolation and structure of Chondramide
Among the myxobacterial compounds is the group of actin binding agents, the Chon-
dramides, originally isolated from myxobacterium Chondromyces crocatus [24]. Structurally,
they are C-18 cyclodepsipeptides consisting of a tripeptide with Ala-Trp-Tyr-sequence
closed to a circle via a polyketide (Figure 1.2). The major derivatives are Chondramide A-D
that differ in a methoxylation at the ring or a chloration at the Tyr side chain (Figure 1.2)
[25, 24].
Figure 1.2: Chemical structure of Chondramide A to D
1.5.2 First cellular studies with Chondramide
So far, it is known that Chondramides bind actin competitively to Phalloidin and accelerate
actin polymerization in pyrene assay [26]. On a cellular level, Chondramides inhibit pro-
liferation of cancer cells, induce actin lumps [26] and fluorescently labeled Chondramide
preferably binds stress fibers [27]. However, detailed mechanisms on anti-cancer activity
are unknown.
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During tumor development, actin plasticity is highly required in angiogenesis and metasta-
sis revealing those as interesting processes to target.
1.6.1 Angiogenesis
Angiogenesis is defined as the formation of new blood vessels from already existing ones.
This formation of new vessels is involved in natural processes like reproduction, develop-
ment and wound repair, as well as pathological processes such as autoimmune diseases,
age-related macular degeneration, atherosclerosis and cancer [28]. In all non-malignant
processes, a balance of pro- and anti-angiogenic signals keeps the endothelium quiescent.
However, in cancer tissue insufficient supply of nutrients causes an elevated release of pro-
angiogenic factors. Those factors, like for example the vascular endothelial growth factor
(VEGF) stimulate quiescent endothelial cells starting the angiogenic cascade (Figure 1.3).
Thereby, endothelial cells get activated and start to proliferate. Extracellular matrix (ECM)
becomes degraded and endothelial cells migrate towards a chemotactic gradient. From
those, tubes are formed and, finally, the established vasculature gets stabilized. [29]
Figure 1.3: The angiogenic cascade. In the process of angiogenesis, angiogenic factors
(AF) stimulate quiescent endothelial cells (1), which start to proliferate (2), to degrade
extracellular matrix and migrate along the chemotactic gradient (3). Endothelial cells
form tubes (4), which, finally, get stabilized and supply the tumor with nutrients and
oxygen (5).
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1.6.2 Metastasis
In case of insufficient angiogenesis or the supply of nutrients, cancer cells are able to trans-
form to a motile phenotype and invade the tumor surrounding tissue initiating metastasis.
After the first transformation and the local invasion, metastizing cells intravasate into blood
vessels. In those, cells need to survive in the circulation and, finally, get trapped in capillar-
ies, e.g. in the lung or liver. Here, tumor cells adhere and extravasate from the vessel to in-
vade the surrounding tissue. Within the new host tissue, cells need to adapt and proliferate
to form new colonies, named metastasis. All these steps are necessary for the development
of metastasis and each can be rate limiting or stop the whole process (Figure 1.4). [30, 31]
Figure 1.4: The metastatic cascade. For the development of metastasis, cancer cells
need to acquire invasive properties (1), invade normal tissue (2), intravasate into blood
vessels (3), survive during circulation (4), adhere and extravasate (5) and, finally, adapt
and proliferate in new tissues (6).
1.6.3 Cell migration
In angiogenesis as well as metastasis the migration of endothelial or cancer cells, respec-
tively, is a major step contributing to the progression of cancer. Cellular migration is a repet-
itive process of five major steps [32, 33]. First, cells sense chemotactic stimuli, protrude in
that direction, attach to new surfaces, contract the rear in the direction of migration and, fi-
nally, release adhesions at the rear to proceed (Figure 1.5 A). In all these processes, the actin
cytoskeleton represents the major structure determining element. Sensing is mediated by
filopodia which are thin long fingerlike membrane protrusions mediated by long parallel
actin bundles (Figure 1.5 A, B). Second, cellular protrusion is accomplished via lamellipo-
dia, a 2 µm thick, dense actin-network at the leading edge pushing the membrane into the
7
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direction of migration. And third, cellular contraction is facilitated by thick actin strands
throughout the cell body called stress fibers. Those stress fibers end up at sites of adhe-
sion interacting with the assembly and disassembly of the adhesive structures called focal
adhesions. [32, 34]
Figure 1.5: Cellular migration. A: Illustration of the five steps within a migratory cycle.
Actin structures are displayed in red, focal adhesions in green and the nucleus in blue.
B: Actin staining of HMEC-1 showing the most representative actin structures (red):
F: filopodia, L: lamellipodia, S: stress fibers. Bar represents 20 µm.
For metastatic cells, additional migration modes are described in 3D environment. Inva-
sive cells show two modes of migration in 3D: first, the mesenchymal type and, second, the
amoeboid type of migration [35, 36, 37]. In the mesenchymal migration, cells show an elon-
gated morphology with lamellipodial protrusions and high proteolytic activity. Contrarily,
the amoeboid migration mode is totally independent of proteolysis and can be induced as
an escape mode when proteolysis is inhibited. In this migration type, cells show rounded
shape and invasion through the matrix is only mediated via cellular contractility. The un-
derlying signaling pathway involves Rho/ROCK and myosin to induce the actin dependent
contractile force which will be explained in the next paragraph. In both processes, the actin
cytoskeleton plays a central role either for the formation of protrusions or the contraction of
the cell. Therefore, the actin machinery represents an attractive target to address metastatic
cells.
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1.6.4 Signaling regulating actin in cell migration
The formation of actin structures is highly regulated. Chemotactic, haptotactic or mechanic
stimuli are transmitted to intracellular molecular switches which further affect actin modify-
ing proteins. Those molecular switches are RhoGTPases that belong to the Ras super family
and are only active in the GTP bound state [38]. The transition between GDP and GTP
binding, and thus its activity, is modified by guanine nucleotide exchange factors (GEFs)
towards GTP binding state and GTPase activating proteins (GAPs) favoring the GDP bound
state. The most important RhoGTPases in migration are Rac1, Cdc42 and RhoA (Figure 1.6).
Rac1 is the main factor for the formation of lamellipodia. Rac1 activates the branching factor
Arp2/3 via WAVE as well as via Cortactin which recruites the Arp2/3 complex leading to
a thick branched filament network. For the formation of filopodia, the RhoGTPase Cdc42
is responsible which activates the LIM kinase (LIMK) via PAKs, finally, inhibiting the actin
severing protein Cofilin. Stress fibers are regulated by the RhoGTPase Rho which mediates
contraction by the inhibition of Cofilin via the Rho associated protein kinase (ROCK) and
LIMK as well as the activation of myosin via ROCK and myosin light chain phosphatase
(MLC phosph.) and the nucleator mDia. [39, 40, 41]
Figure 1.6: Signaling downstream to RhoGTPases Rac1, Cdc42 and Rho.
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The RhoGTPases itself are activated via extracellular stimuli that are transmitted either by
tyrosin kinases, G protein-coupled receptors or integrins. Thus, extracellular growth factors
bind to the membranous receptor tyrosine kinase (RTK), which autophosphorylates and ac-
tivates PI3 kinases (PI3K). PI3K converts phosphatidylinositol-4,5-bisphosphate (PIP2) to
phosphatidylinositol-3,4,5-triphosphate (PIP3) which binds GEFs, activates them, finally
leading to RhoGTPase activation. Other stimuli like lysophosphatidic acid (LPA) bind to
G protein-coupled receptors, thereby, releasing G12/13 which in turn binds and activates
Rho-GEFs. [42, 43]
Additionally to soluble factors, extracellular matrix can also lead to RhoGTPase activation
like during adhesion (Figure 1.7 A). The binding of integrins to ECM activates integrins al-
lowing the attachment of signaling molecules in the cytoplasm. Thus, after new attachment,
the focal adhesion kinase binds the intracellular part of integrins leading to autophosphory-
lation of FAK. Consequently, Src is recruited resulting in further phosphorylations of FAK,
establishing additional protein binding sites and full activity of the FAK/Src complex [44].
This complex further phosphorylates other proteins like p130Cas or paxillin which then bind
GEFs to an active complex or phosphorylates GEFs to activate Rac1 for cell spreading. At
later stages of adhesion, integrin-mediated activation of GEFs induces RhoA activation ini-
tiating contractility [45, 46]. In addition to adhesion, mechanical stimuli, stretching or shear
stress, activate Rho via integrins at which Vav2 is one of the involved GEFs (Figure 1.7 B)
[47, 48].
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Figure 1.7: Activation of RhoGTPases via integrin signaling. A: Activation of Rho-
GTPases during cell spreading. In the early phase of spreading, the complex of FAK
and Src forms at the intracellular domain of integrins and phosphorylates p130Cas and
Paxillin which, finally, activate GEFs and, thus, Rac1. At later stages, Src initiates Rho
activity. B: Activation of Rho via force. Either extracellular or intracellular forces can
induce Rho activity via the GEF Vav2.
11
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1.7 Aim of the study
Tumor angiogenesis and cancer cell metastasis are major processes contributing to the pro-
gression of cancer. Both processes involve the migration of cells and, thus, high plasticity
of the actin cytoskeleton. Therefore, actin is an interesting target to adress for the inhibition
of angiogenesis or metastasis. Chondramide is a natural compound from myxobacteria that
binds actin and disturbs actin turnover.
The aim of this study was to evaluate the potential of Chondramide to inhibit angiogen-
esis and metastasis. For this purpose, endothelial cells should be tested on characteristic
angiogenic features like proliferation, migration and tube formation under Chondramide
treatment. Next, the responsible actin structures should be evaluated on their response on
Chondramide treatment to explain functional changes. Further, the signaling cascades in-
volved in the migration process and actin regulation were tested on their response to Chon-
dramide treatment.
Concerning metastasis, the impact of Chondramide on cancer cell migration and invasion
was tested. To answer the question, how functional changes are generated by Chondramide,
responsible actin structures were investigated as well as important signaling components.
Further, the consequences of Chondramide on the migration of cancer cells in a 3D environ-
ment were evaluated.
Concluding, this work aimed to investigate the anti-angiogenic and anti-metastatic potential
of the actin binding compound Chondramide and to examine the underlying intracellular
mechanisms causing the cellular response.
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Figure 1.8: Aim of the study. The myxobacterial compound Chondramide binds actin
and leads to its overpolymerization. The impact of Chondramide on tumor angiogen-
esis and metastasis was evaluated. Thereby, Chondramide was tested on its impact on
cellular functionality, the corresponding actin structures and the underlying signaling.
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2.1 Materials
2.1.1 Compounds
Chondramides were isolated and provided from the group of Rolf Müller [49]. Chon-
dramide A and B (ChA, ChB) were dissolved and stored in DMSO and dissolved in growth
medium for experiments containing DMSO at a maximum of 0.1% (v/v). Jasplakinolide
(Jk) was purchased from Enzo Life Sciences (Lörrach, Germany) and Cytochalasin D (Cy-
toD) from AppliChem (Darmstadt, Germany).
2.1.2 Reagents, dyes and inhibitors
Table 2.1: Reagents and dyes
Reagent Producer
Accustain paraformaldehyde Sigma Aldrich, Taufkirchen, Germany
Bovine serum albumin (BSA) Sigma Aldrich, Taufkirchen, Germany
Bradford ReagentTM Bio-Rad, Munich, Germany
Dimethylsulfoxide (DMSO) AppliChem, Darmstadt, Germany
Epidermal growth factor (EGF) PeproTech Inc., Rocky Hill, NJ, USA
EGTA-K AppliChem, Darmstadt, Germany
FluorSaveTM Reagent mounting medium Merck, Darmstadt, Germany
Formaldehyde, 16% ultrapure Polysciences Europe GmbH, Eppelheim,
Germany
Glutaraldehyde Merck, Darmstadt, Germany
MatrigelTM BD Biosciences, Heidelberg, Germany
Non-fat dry milk powder (Blotto) Carl Roth, Karlsruhe, Germany
Page RulerTMPrestained Protein Ladder Fermentas, St. Leon-Rot, Germany
Propidium iodide Sigma Aldrich, Taufkirchen, Germany
Triton X-100 Merck, Darmstadt, Germany
Tween R© 20 BDH/Prolabo R©, Ismaning, Germany
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All other biochemicals and dyes used in this work were purchased from Sigma-Aldrich,
AppliChem, Carl Roth or Merck.
Table 2.2: Inhibitors used in the study
Inhibitor Producer
Aprotinin Sigma Aldrich, Taufkirchen, Germany
Complete R© mini EDTA free Roche diagnostics, Penzberg, Germany
Leupeptin hemisulfate salt Sigma-Aldrich, Taufkirchen, Germany
Na3VO4 ICN Biomedicals, Aurora, OH, USA
NaF Merck, Darmstadt, Germany
Phenylmethylsulfonyl fluoride (PMSF) Sigma Aldrich, Taufkirchen, Germany
Saracatinib (AZD-0530) Selleck Chemicals, Houston, USA
Table 2.3: Cell culture reagents
Cell culture reagent Producer
Amphotericin B 250 µg/ml AppliChem, Darmstadt, Germany
Collagen G Biochrom AG, Berlin, Germany
Collagenase A Roche, Mannheim, Germany
Dulbecco’s modified Eagle’s medium
(DMEM)
Sigma Aldrich, Taufkirchen, Germany
Endothelial Cell Growth Medium (ECGM)
with Supplement Mix C-39215
PromoCell, Heidelberg, Germany
FCS gold PAA Laboratories, Pasching, Austria
FCS PAN Biotech, Aidenbach, Germany
M199 medium PAA Laboratories, Pasching, Austria
Penicillin/Streptomycin 100x PAA Laboratories, Pasching, Austria
RPMI 1640 PAN Biotech, Aidenbach, Germany
Trypsin PAN Biotech, Aidenbach, Germany




2.2.1 Solutions and reagents
For the cultivation of cells, solutions were used in the following compositions:
Table 2.4: Cell culture solutions
Solution Composition
PBS (pH 7.4) NaCl (123.3 mM),
Na2HPO4 (10.4 mM),
KH2PO4 (3.2 mM) in H2O
PBS+ Ca2+/Mg2+ (pH 7.4) NaCl (136.9 mM), KCl (2.7 mM),
Na2HPO4 (8.1 mM),
KH2PO4 (1.5 mM),
MgCl2 (0.5 mM), CaCl2 (0.7 mM) in H2O




Streptomycin (10%) in ECGM
DMEM FCS gold (10%),
Penicillin (10,000 U/ml),
Streptomycin (10%) in DMEM
RPMI FCS gold (10%),
non-essential amino acid (1%),
pyruvate (1%),
human insulin (10 µg/ml) in RPMI 1640
Stopping medium FCS (10% in M199
Trypsin/EDTA Trypsin (0.05%), EDTA (0.02%) in PBS
Collagen G Collagen G (0.001%) in PBS
Collagenase A (HUVEC isolation) Collagenase A (0.01%) in PBS+ Ca2+/Mg2+
2.2.2 Endothelial cells
As endothelial cell line CDC/EU.HMEC-1 (HMEC-1) were used. The cell line was es-
tablished from primary isolated human dermal microvascular endothelial cells (HMEC)
immortalized via transfection of BR-322-based plasmid containing the coding region for
the simian virus 40 A gene product [50, 51]. HMEC-1 were kindly provided by Centers for
Disease Control and Prevention (Atlanta, GA, USA), passaged twice a week in a ratio of 1:4
and used until passage 12.
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For adhesion related experiments, the primary cells, human umbilical vein endothelial cells
(HUVECs), were used isolated from the umbilical cord vein. Human umbilical cords were
kindly provided by Klinikum München Pasing, Wolfart Klinik Gräfelfing, Frauenklinik Dr.
Krüsmann München and Rotkreuzklinikum München in accordance with the declaration of
Helsinki. Umbilical cords were stored in PBS+ Ca2+/Mg2+ containing Penicillin (100 U/ml)
and Streptomycin (100 µg/ml) at 4◦C for maximal 1 week until usage. For isolation, the um-
bilical vein was first washed with PBS+ Ca2+/Mg2+, filled with 0.1 g/l collagenase A, and
incubated for 45 min at 37◦C. Collagenase was stopped and endothelial cells were washed
out by flushing the vein with stopping medium. For cultivation, endothelial cells were
centrifuged (1000 rpm, 5 min, RT), resolved in ECGM and plated in a 25 cm2 flask. After
reaching confluency, cells were transfered to a 75 cm2 flask. For experiments, HUVECs were
used at passage 3.
All endothelial cells (ECs) were cultured under constant humidity at 37◦C and with 5% CO2
in an incubator (Heraeus, Hanau, Germany). As cell culture medium, endothelial cell
growth medium (ECGM, Promocell, Heidelberg, Germany) was used.
2.2.3 Cancer cells
Concerning metastasis, the highly invasive cancer cell line MDA-MB-231 was used. This
cell line, isolated from breast carcinoma metastasis via pleural efusion, shows negative ex-
pression of estrogen, progesterone and HER-2 receptor and a highly invasive mesenchymal
phenotype [52, 53, 54]. MDA-MB-231 cells were purchased from Cell Line Services (Eppel-
heim, Germany), cultivated in DMEM and passaged twice a week in a ratio of 1:10.
For comparison of migration inhibition, the cancer cell lines MCF-7 (breast cancer), L3.6pl
(pancreatic cancer) and HUH-7 (hepatic cancer) were used. HUH-7 cells (JCRB0403, JCRB,
Tokyo, Japan) were cultured in DMEM and passaged twice a week in a ratio of 1:5. MCF-7
(ACC 115, DSMZ, Braunschweig, Germany) were cultured in RPMI and passaged twice a
week in a ratio of 1:10. L3.6pl were provided by Christine J. Bruns (Department of Surgery,
Klinikum Grosshadern, LMU Munich, Germany), cultivated in RPMI and passaged twice a
week in a ratio of 1:10.
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All cancer cell lines were cultured under constant humidity at 37◦C and with 5% CO2 in an
incubator (Heraeus, Hanau, Germany).
2.2.4 Passaging
For passaging, medium was removed, cells were washed twice with PBS, trypsin/ethylene
diamine tetraacetic acid (EDTA) (T/E) was added and incubated at 37◦C. After 3 min
incubation, digestion was stopped by adding stopping medium. Cells were centrifuged
(1000 rpm, 5 min, RT), resuspended in ECGM and, finally, transfered to a new flask or seeded
for experiments.
2.2.5 Freezing and thawing
For long time storage, confluent HMEC-1 or cancer cells from a 75 cm2 flask were trypsinized,
centrifuged (1000 rpm, 5 min, RT) and resuspended in 3 ml ice-cold freezing medium. 1.5 ml
aliquots were frozen in cryovials and stored at -80◦C for 24 h before being moved to liquid
nitrogen for longtime storage.
In order to thaw cells, cryovials were warmed up to 37◦C and the content was immedi-
ately dissolved in the appropriate, prewarmed culture medium. DMSO was removed via




HMEC-1 (1.5 x 103 cells/well) were seeded in a 96-well plate. After 24 h, cells were treated
with the indicated concentrations of Ch and incubated for 72 h. Finally, cells were washed
with PBS, incubated with 100 µl/well crystal violet solution (0.5% (w/v) crystal violet, 20%
(v/v) methanol in H2O) for 10 min, washed and dried. For solvation of crystal violet,
100 µl/well ethanol/Na-citrate solution (50% ethanol, 50% 0.1 M Na-Citrat in H2O) were





For scratch assay, confluent HMEC-1 were scratched using a pipette tip and treated as indi-
cated. Endothelial cells were allowed to migrate for 13 h, then fixed with 4% (v/v) para-
formaldehyde (p-FA) and images were taken using TILLvisION system (Lochham, Ger-
many) in connection with an Axiovert 200 microscope (Zeiss, Jena, Germany). Images were
analyzed by Wimasis GmbH (Munich, Germany). Migration was quantified as the percent-
age of the cell covered area compared to the total image area.
2.3.3 Chemotaxis assay
For chemotaxis assay, 50 x 103 HMEC-1 were seeded in a µ-slide chemotaxis (ibidi GmbH,
Munich, Germany). After 2 h, a gradient between 0 to 30% (v/v) FCS was applied according
to manufacturer’s instructions. Images were taken every 10 min for 20 h using an open U-
iMIC microscope (TILL Photonics, GmbH, Gräfelfing, Germany), 10x objective. Images were
analyzed employing the ImageJ plugin Chemotaxis tool.
2.3.4 Tube formation assay
In order to analyze the ability of endothelial cells to form tube structures, tube formation
assay was performed. Therefore, 11 x 103 HMEC-1 were seeded on matrigel (MatrigelTM,
Schubert&Weiss-OMNILAB, Munich, Germany) in an angiogenesis slide from ibidi (Mu-
nich, Germany), treated as indicated and incubated for 15 h. Images were taken using the
TILLvisION system. Analysis of images was performed by Wimasis GmbH (Munich, Ger-
many). For time lapse imaging, the open U-iMIC microscope was used with a stage incu-
bator. As parameters of tube formation, tube length, number of nodes and number of tubes
were analyzed.
2.3.5 Adhesion assay
Pretreated HUVECs were trypsinized, suspended in DMSO or Ch containing ECGM and
allowed to adhere on fibronectin or collagen for 30 min. Cells were fixed with 4% (v/v)
p-FA and stained for F-actin. Images were taken (10x objective; Zeiss LSM 510 META
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confocal microscope, Jena, Germany) and counted for adhering cells. Cell morphology
was distinguished in normal spreading cells (normal), irregular shaped cells, showing non-
symmetrical spreading (irregular), and completely rounded cells (globular).
2.4 Metastasis assays
2.4.1 Scratch assay
The migration of cancer cells was analyzed analogue to endothelial cell migration in scratch
assay. Only the time for scratch recovery was different for each cell line at which MDA-
MB-231 cells were incubated for 24 h, MCF-7 for 30 h and L3.6pl as well as HUH-7 cells for
27 h.
2.4.2 Boyden chamber assay
In order to follow cancer cell migration towards a growth factor gradient, Boyden chamber
assay was used. For this purpose, 5 x 104 MDA-MB-231 cells were seeded per well in a
Boyden chamber (Corning, New York, USA) without FCS. For negative control, the lower
compartment was filled with medium lacking FCS, whereas for positive control and treated
samples, the lower compartment was filled with full medium containing 10% (v/v) FCS. Af-
ter 16 h, cells were fixed and stained with crystal violet/methanol (see proliferation assay).
Cells on top of the filter were removed with a q-tip and bottom sides were photographed us-
ing an Axiovert25 microscope (Zeiss), 10x objective, and a Canon EOS 450C camera (Tokyo,
Japan). Images were analyzed using the ImageJ plugin cell counter.
2.4.3 Invasion assay
The invasion assay was performed analogue to Boyden chamber assay except for filters be-
ing filled with 100 µl 10% (v/v) matrigel (Schubert&Weiss-OMNILAB, Munich, Germany).
Matrigel was allowed to polymerize for 1 h at 37◦C before cell seeding. Cellular invasion
was incubated for 48 h.
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2.4.4 Adhesion assay
Pretreated MDA-MB-231 cells were trypsinized, suspended in DMSO or Ch containing
medium and allowed to adhere on fibronectin, collagen G or plastic for 1 h. Cells were fixed
with 4% (v/v) p-FA and stained for F-actin. Images were taken on a Zeiss LSM 510 META
confocal microscope (10x objective) and counted for adhering cells.
2.5 Flow cytometry (FACS)
Flow cytometry was used to measure the amount of apoptotic cells or surface proteins.
2.5.1 Measurement of sub-diploid DNA content
To detect apoptotic cells, sub-diploid DNA content (i.e. fragmented nuclei) was measured as
described by Nicoletti et al. [55]. Thereby, HMEC-1 were seeded in a 24-well plate (70 x 103
cells/well), grown over night and treated with Ch. After 48 h, cells were harvested (200 µl
T/E per well for 2 min, 500 µl stopping medium), transfered to a FACS tube and washed
with cold PBS (1ml/tube, centrifugation: 600g, 10 min, 4◦C). For nuclei staining, 250 µl per
well HFS-PI solution (0.1% (v/v) Triton X-100, 0.1% (w/v) sodium citrate, 50 µg/ml propid-
ium iodide) was added and incubated for 45 to 60 min. Sub-diploid DNA content was mea-
sured by flow cytometry using a FACSCalibur (Becton Dickinson, Heidelberg, Germany)
and analyzed using the Flow cytometry analysis software FlowJo 7.6.
2.5.2 Measurement of membraneous, extracellular proteins
For the measurement of extracellular integrins, HUVECs were seeded in a 24-well plate
(60 x 103 cells/well), grown over night and stimulated with Ch for 4 h. Cells were harvested
on ice (see 2.5.1), transfered to a FACS tube and washed (2.5.1). For staining, 30 µl/tube of
antibody for total integrin β1 (1:400 in 0.01% BSA/PBS, Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA) or active integrin β1 (1:400 in 0.01% BSA/PBS, Abcam Inc., Cambridge,
MA, USA) were added per sample and incubated for 45 min at 4◦C. Samples were washed
and incubated with secondary antibody (Alexa Fluor R© 488 Goat anti-mouse IgG, Molecular
Probes, Darmstadt, Germany, 1:400 in 0.01% BSA/PBS) for 45 min protected from light.
21
2.6 Propidium iodide staining for microscopy
After a final washing step, samples were resuspended in 250 µl PBS and analyzed by flow
cytometry using a FACSCanto II (Becton Dickinson, Heidelberg, Germany) and the mean
fluorescence was calculated using the Diva-Software of BD Bioscience (San Jose, CA, USA).
2.6 Propidium iodide staining for microscopy
In order to test the membrane integrity, propidium iodide staining of adherent cells was
performed. Therefore, 30 x 103 HMEC-1 were seeded in a 24-well plate and incubated over
night. After Ch stimulation, propidium iodide was added to the medium to a final concen-
tration of 10 µg/ml for 15 min. For positive control, additional Triton X-100 was added (final
concentration 0.02% (v/v) in PBS). Pictures were taken on a fluorescent microscope with 10x
objective.
2.7 Transfection of cells
For the transfection of endothelial cells the Targeffect-HUVEC kit (Targetingsystems, El Ca-
jon, CA, USA) was used. 70 x 103 HUVECs were seeded in a µSlide from ibidi and incubated
over night. For transfection complex, 800 µl DMEM were supplemented with 800 ng plas-
mid DNA (pLifeAct-TagGFP, ibidi), 1.6 µl F2 reagent and 3.2 µl virofect enhancer at which
flicking the tube 10x after each addition. After transfection complex formation, the mix-
ture was incubated 25 min at 37◦C, medium of cells was removed and 200 µl of transfection




2.8.1 Microscopy with fixed cells
In order to visualize the localization of a certain protein within the cell, immunohistochem-
istry was performed.
Cells were seeded and treated in µ-slides from ibidi. For staining, samples were washed
once with PBS+ (RT), fixed (see below) and washed again with standard PBS. Permeabiliza-
tion followed if necessary with 0.1% (v/v) Triton X-100 for 2 min at RT and a washing step
of 10 min with PBS. Next, samples were blocked with 0.2% (v/v) BSA (PBS) for 15 min at RT
before incubation with primary antibody. Primary antibodies (150 µl/well) were added in
dilutions as indicated in 0.2% (v/v) BSA (Table 2.5) and incubated either for 1 h at RT or over
night at 4◦C, shaking. After washing three times with PBS for 5 min each, the secondary an-
tibody was applied (150 µl/well, 0.2% (v/v) BSA) together with rhodamin-phalloidin and
Hoechst for 45 min at RT, shaking. Samples were washed thrice, 5 min each, with PBS, and,
finally, sealed with mounting medium (FluorSaveTM Reagent, Merck Millipore) and cover
slip. Samples were kept at 4◦C for longer storage.
For fixation, different methods were used depending on the target recognition of the ap-
plied antibody. For fixation with p-FA, samples were incubated either with 4% (v/v) p-FA
for 10 min at RT or with 1% (v/v) p-FA for over night at 4◦C and permeabilized with Tri-
ton X-100 afterwards. In case of aceton or methanol fixations, samples were incubated with
prechilled aceton or methanol at -20◦C for 10-15 min without incubation with Triton after-
wards.
In case of single F-actin staining, samples were treated as described, however, blocking and
primary antibody were skipped and rhodamin-phalloidin was solved in PBS.
Images were obtained using a Zeiss LSM 510 META confocal microscope (Zeiss, Jena, Ger-
many) or a Leica TCS SP8 (Leica Microsystems, Wetzlar, Germany).
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Table 2.5: Primary antibodies for immunohistochemistry
Antibody Provider Fixation Dilution
Anti-Cortactin (3503) Cell signalling p-FA 1:100
Anti-Integrin α2β1 (ab30483) Abcam p-FA 1:1000
Anti-Integrin α5 (AB1928) Millipore, Upstate p-FA 1:1000
Anti-LAMP-1 (H4A3) Dev. St. Hybridoma p-FA 1:400
Anti-pp(T18S19)-MLC (3674) Cell signalling p-FA 1:200
Anti-p21-Arc (612234) BD Biosciences Methanol 1:100
Anti-Rab5A (S-19, sc-309) Santa Cruz p-FA 1:200
Anti-α-tubulin (ab18251) Abcam Aceton 1:400
Anti-γ-tubulin (T 6557) Sigma Methanol 1:2000
Anti-VE-cadherin (sc-9989) Santa Cruz p-FA 1:400
Table 2.6: Secondary antibodies or dyes for immunohistochemistry
Antibody/Dye Provider Dilution
Alexa Fluor 488 chicken anti-goat IgG (H+L) Invitrogen 1:400
Alexa Fluor 488 goat anti-mouse IgG (H+L) Invitrogen 1:400
Alexa Fluor 488 goat anti-rabbit IgG (H+L) Invitrogen 1:400
Hoechst (bisBenzimide H33342) SigmaAldrich 1.400
Rhodamin-phalloidin (R 415) Invitrogen 1:400
2.8.2 Life cell imaging
To follow actin dynamics during the migration process, life cell imaging was performed.
HUVECs were transfected with pCMV-LifeAct-TagGFP (ibidi, Munich, Germany) and
seeded in µslides. Upon confluency, the cell monolayer was scratched and samples were
mounted on an open U-iMIC microscope with climate chamber. Images were taken every
10 min for several hours. Movies were analyzed using ImageJ.
2.8.3 Histological stainings
For the visualization of tumoral vasculature, cryosections were stained. Tumors embedded
in FrozenSection Medium Neg50 (Thermo Scientific) were sliced into sections of 10 µm.
Cryo-slices were allowed to dry for 15 min at RT, washed with PBS for 2 min and fixed with
4% (v/v) p-FA for 10 min at RT. Permeabilization and blocking occured in one step with
2% (v/v) BSA, 0.5% (v/v) Triton X-100 in PBS for 30 min at RT. CD31 was stained with a
rat anti-mouse CD31 antibody (553370, BD Biosciences, San Jose, USA, 1:100) over night at
4◦C. Slices were washed twice for 7 min with PBS and secondary antibody (goat anti-rat 546,
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1:400) was mounted for 2 h at RT together with Hoechst (1:400). Samples were washed (2x,
7 min, PBS), washed once with water and sealed with mounting medium and cover slip.
Images were taken using a Zeiss LSM 510 META confocal microscope.
2.9 Measurement of cellular contractility
For the measurement of cellular contractility, an assay was performed adapted from
Poincloux et al. [56]. Thereby, cells were embedded in matrigel containing fluorescent
beads. Cellular force on the surrounding matrix results in bead movement which can be
tracked by time lapse imaging and analyzed afterwards.
2.9.1 Contractility assay
To this end, MDA-MB-231 cells were pretreated with Ch and labeled with CellTrackerTM Red
(LifeTechnologies, Carlsbad, CA, USA) (5µM) for 30 min. Next, yellow-green microbeads
of 1 µm diameter, 2% solids (LifeTechnologies) were mixed with matrigel in a ratio of 1:4
(v/v) on ice. The bead/matrigel mixture was mixed with pretreated, labeled MDA-MB-231
cells, 5 x 106 cells/ml, in a ratio of 2:1 (v/v) and pipetted in an angiogenesis slide (ibidi).
Matrigel containing cells was allowed to polymerize for 1 h at 37◦C, 5% CO2 in humidified
atmosphere, before samples were covered with culture medium. Images were taken using
an open U-iMIC fluorescent microscope (TILL Photonics GmbH, Gräfelfing, Germany) with
a climate chamber and 20x objective. One z-stack per well was recorded and chosen cells
had a minimum distance of 20 µm to the edge of matrigel and sufficient space between cells
to not disturb bead movement. Stacks of 5 slices around the cell equatorial plane with a
2 µm distance were taken over 4 h with 15 min intervals.
Figure 2.1: Scheme of experimental setting for contractility assay.
25
2.9 Measurement of cellular contractility
2.9.2 Image processing
Recorded stacks were processed for further analysis via imageJ. First, three out of five optical
slices around the equatorial plane of the cell were selected (command: make substack) and
projected in one plane (command: maximum intensity projection), once for cell channel and
once for bead channel. Shifts in the xy plane were removed (plug in: image stabilizer) first
for the beads, and the recorded shift was tranfered to the cell stack. Next, the two stacks,
beads and cells, were fused to an hyperstack and croped to standardized 300 x 300 px with
one cell at the image center. The bead channel was used for analysis.
2.9.3 PIV analysis
Movies of fluorescent beads were analyzed by particle image velocimetry (PIV) analysis per-
formed by Matthias Zorn (Department of Physics, LMU, Munich).
Thereby, a customized MatPIV software package for Matlab was used. Interrogation win-
dows were 32 x 32 pixels, i.e. 21 x 21 µm. A single iteration was performed with 62.5%
overlap. The resulting velocity vectors were filtered with the set of filters included in the
standard MatPIV package to smooth the vector fields. As the sample observation is re-
stricted to 2D, z-components of the velocity are not seen and the PIV analysis only gives
velocities projected into the observation plane. The obtained velocity field was averaged on
each grid point over each frame of the observation period to further remove fluctuations
that occur on short time scales. For quantitative comparison, the sum of values of particle
displacement towards the cell center was calculated for each cell.
Minimum 13 cells per condition out of three independent experiments were recorded and
analyzed.
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2.10 Western blot analysis
For the detection of proteins in cell lysates, Western blot analysis was performed. Protein
quantification of cell lysates was performed as described by Bradford [57]. Equal amounts
of proteins were loaded on sodium dodecyl sulfate (SDS)-gels and separated via SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) using Bio-Rad System (Munich, Germany)
(20 min: 100 V, 45 min: 200 V) [58]. For protein transfer from SDS gel to nitrocellulose
membrane tank blot (Bio-Rad System) was used. For most proteins blotting occured at 1.5 h
and 100 V except for MLC2 and its phosphorylated forms for which 1 h at 130 V was used.
Protein detection was performed either using ECL detection system (Amersham Pharmacia
Biotech) or Odyssey Infrared Imaging system version 2.1 (LI-COR Biosiences, Lincoln, NE,
USA).
Table 2.7: Western blot buffers
Solution Composition
RIPA lysis buffer TrisHCl (pH 7.4) (50 mM), NaCl (150 mM)
Nonidet NP 40 (1%), Deoxycholic acid (0.25 %)
SDS (0.1%), Na3VO4 (0.3 mM)
NaF (1 mM), β-glycerophsophate 3 mM
Complete R© mini EDTA free (4 mM)*
PMSF (1 mM)*, H2O2 (0.5 mM)*, in H2O
5x SDS sample buffer TrisHCl (pH 6.8) (3.125 mM), Glycerol (10 ml)
SDS (5%), DTT (2%)
PyroninY (0.025%), in H2O
3x Laemmli buffer Tris/HCl (pH 6.8) (137.5 mM), Glycerol (30%)
SDS (6%), Bromphenol blue (0.025%)
β-Mercaptoethanol (12.5%)*
Electrophoresis buffer Tris (4.9 mM), Glycine (38 mM)
SDS (0.1%), in H2O
Tank buffer 5x TrisBase (240 mM), Glycine (195 mM), in H2O
Tank buffer 1x Tank buffer 5x (20%), Methanol (20%), in H2O
*added right before usage
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Table 2.8: Primary antibodies for Western blot analysis
Antigen Source Dilution Solvent Provider
Akt (9272) rabbit 1:1000 5% Blotto Cell Signalling
Akt pS473 (4051) mouse 1:500 5% Blotto Cell Signalling
EGF-R (4267) mouse 1:500 1% Blotto Cell Signalling
EGF-R pY1068 (3777) rabbit 1:500 1% Blotto Cell Signalling
Erk (9102) rabbit 1:1000 5% Blotto Cell Signalling
Erk pT202,Y204 (9106) mouse 1:1000 5% Blotto Cell Signalling
FAK (sc-1688) mouse 1:500 5% Blotto Santa Cruz
FAK pY397 (sc-11765-R) rabbit 1:500 5% BSA Santa Cruz
FAK pY576/577 (sc-21831-R) rabbit 1:500 5% Blotto SantaCruz
GAPDH (sc-69778) mouse 1:1000 5% Blotto Santa Cruz
MLC2 (FL-172) (sc-15370) rabbit 1:500 5% Blotto Santa Cruz
MLC2 p(S19) (3675) mouse 1:1000 5% Blotto Cell Signalling
Rac (23A8) mouse 1:1000 5%Blotto,
0.1% Tw20
Merck Millipore
Rho (16116) rabbit 1:667 3% BSA Thermo Scientific
Src (2110) mouse 1:1000 5% Blotto Cell Singalling
Src pY416 (6943) rabbit 1:1000 5% BSA Cell Singalling
Vav2 (F-6) (sc-271442) mouse 1:200 5% BSA Santa Cruz
Vav2 pY172 (sc-16409-R) rabbit 1:200 5% BSA Santa Cruz
Table 2.9: Secondary antibodies for Western blot analysis
Antibody Dilution Solvent Provider
Goat anti-mouse IgG1 HRP 1:1000 5% Blotto Biozol
Goat anti-mouse HRP 1:10 000 5% Blotto Dianova
Alexa Fluor R© 680 Goat anti-mouse IgG 1:20 000 1% Blotto Molecular Probes
Alexa Fluor R© 680 Goat anti-rabbit IgG 1:20 000 1% Blotto Molecular Probes
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2.11 Pull down assay
For endothelial cells, one 75 cm2-flask of confluent HUVECs was splitted into three 75 cm2-
flasks and grown for 16 h. The subconfluent cells were treated with Ch for 4 h and seeded
freshly into 10 cm-dishes (coated with collagen G) and allowed to adhere for 30 min in order
to activate RhoGTPases. All following steps were performed on ice at 4◦C. Cells were lysed,
harvested and a pull down assay according to manufacturer’s protocol (Thermo Scientific,
Bonn, Germany).
In case of cancer cells, MDA-MB-231 cells were seeded in a 6-well plate (400 x 103 cells/well)
and grown for several hours. The activation of Rac1 and Rho was induced by adding
100 ng/ml EGF for 5 min to the medium followed by a pull down assay.
2.12 Statistical analysis
The number of independently performed experiments and the statistical tests used are
stated in the respective figure legend. Graph data represent means ± SEM. Statistical anal-
ysis was performed with the software GraphPad Prism Version 5.04 (GraphPad Software,
Inc., La Jolla, CA, USA). Statistical significance is assumed if p ≤ 0.05.
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3: Results
3.1 Chondramide diminishes angiogenesis in vitro and in vivo
3.1.1 Chondramide inhibits proliferation of endothelial cells at nanomolar
concentrations
Initially, we examined the effect of Chondramide (Ch) on endothelial cell proliferation. Here,
we could see that Ch inhibits the proliferation of HMEC-1 at nanomolar concentrations with
an IC-50 value of 82 nM for ChA and 36 nM for ChB (Figure 3.1).
Figure 3.1: Chondramide inhibits proliferation of endothelial cells at nanomolar con-
centrations. Graphs of proliferation of endothelial cells are shown for ChA (A) and B
(B) as well as the actin targeting substances Jasplakinolide (Jk, C) and Cytochalasin D
(Cyto D, D). Half maximal inhibitory concentrations (IC-50) are inserted. (n=3)
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Thus, both substances are very potent, however, ChB shows a slightly higher activity on
proliferation. Interestingly, for both substances the curve showed an extreme sigmoidal
curve slope meaning no effect up to 30 nM followed by an extreme drop to nearly zero
at 100 nM revealing this as an interesting concentration range. Further, we compared the
activity of Ch to the known actin-targeting substances Jasplakinolide (Jk) and Cytochalasin
D (CytoD). As these showed an IC-50 of 27 nM (Jk) and 52 nM (CytoD), respectively, ChA
and B are in a similar range of potency compared to established actin-targeting compounds.
3.1.2 Chondramide diminishes endothelial cell migration but not specifically
chemotaxis
The migration of endothelial cells represents a major step in the process of angiogenesis.
Therefore, we examined the effect of Ch on the migration of endothelial cells. First, a wound
healing assay was performed. The migration of HMEC-1 towards the scratch was inhibited
in a concentration dependent manner up to an inhibition to nearly 50% at 200 nM (Fig-
ure 3.2).
Figure 3.2: Chondramide inhibits migration of HMEC-1 in a concentration dependent
manner. Left panel: Representative images are shown. The area covered with cells is
displayed in green. Right panel: Analysis of images on cell covered area. (One-way
ANOVA, Tukey post-test, * p<0.05, n=3).
Second, the impact on chemotactic properties in the migration towards a gradient of growth
factors was tested. In the chemotaxis assay, migration was significantly inhibited at 100 nM
as seen by a reduction of the mean velocity and the accumulated distance to less than 50%
(Figure 3.3). The chemotactic ability was not affected specifically as the center of mass to-
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wards the gradient was only reduced when cell migration was inhibited. Additionally, the
total passed distance (accumulated distance) and the distance between start and end point
(euclidian distance) were either not (30 nM) or both reduced (100 nM) indicating that Ch has
an overall effect on cell motility but not the chemotactile properties specifically.
Figure 3.3: Chondramide inhibits migration per se but does not diminish chemotactic
properties of HMEC-1 specifically. Upper panel: The analysis of one representative
experiment is shown. Lower panel: Quantitative evaluation of the parameters center of
mass, accumulated distance, euclidean distance and mean velocity. (One-way ANOVA,
Tukey post-test, * p<0.05, n=4).
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3.1.3 Chondramide disrupts tube formation in a concentration and time
dependent manner
To simulate the process of angiogenesis in vitro, endothelial cells were seeded on matrigel
to form tube like structures. End point images showed that the tube structure like in the
DMSO control could not be established with rising concentrations of Ch (Figure 3.4).
Figure 3.4: Chondramide disturbs tube formation in vitro in a concentration depen-
dent manner. Representative images are shown (n=3, 10x objective).
To analyze the underlying process of Ch inhibiting the formation of tubes, we followed
the process over time (Figure 3.5). Cells build a quite dense network of tubes after 4 h as
seen by a high number of tubes, branching points and short tubes. Over time, this network
maturates to a thinner network with fewer tubes, branching points and longer tubes as those
fuse together. In the presence of 100 nM Ch, the establishment of the first network is still
possible, however, the maturation later on is impaired as seen by less reduction of tubes
and branching points. This effect was most obvious after 15 h. At 300 nM, cells could not
even build the first network suggesting that the inhibitory effect of Ch is faster at higher
concentrations and, thus, the process is concentration and time dependent (Figure 3.5).
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Figure 3.5: The maturation of tubes is disturbed by Chondramide. Number of tubes,
number of branching points and tube length were analyzed over time. Left panel: An-
alyzed pictures at different time points (10x objective). Cell covered areas recognized
by the software are indicated in blue, tubes in pink and branching points via yellow
dots. Right panel: Graphs showing the development of analyzed parameters over time.
Dashed line represents the respective values after treatment with DMSO for 15 h. (n=3)
Further, we wanted to know about the integrity of the formed tubes and stained cell-cell
junctions via VE-Cadherin (Figure 3.6). Here, we could see that in tubes formed under
Chondramide treatment (100 nM) the cell-cell contacts were clearly disrupted. This data in-
dicates that Ch interferes with the maturation of tubes and development of cell-cell-contacts.
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Figure 3.6: Cell-cell contacts are disturbed in Chondramide treated tubes. After tube
formation assay (15 h), tubes were stained for F-actin (red), VE-Cadherin (green) and
nuclei (blue). Yellow indicates an overlap of F-actin and VE-Cadherin. Representative
images are shown. Bar represents 20 µm (n=3).
3.1.4 Chondramide leads to actin aggregation forming aggresomes
To get a first insight in the intracellular effect of Ch, stainings of the cytoskeleton were per-
formed. The staining of the actin cytoskeleton revealed an aggregation of the fibrilous actin
by Ch (Figure 3.7). At 30 nM Ch, aggregation was only seen close to the nucleus (arrow)
and earliest after 4 h. However at 100 nM Ch, already after 2 h aggregation occurred in the
cytoplasm followed by a complete retraction of the cells. In contrast, microtubules did not
show any specific difference. At 30 nM and also at 100 nM microtubules changed only due
to deformation of the whole cell.
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Figure 3.7: Chondramide induces actin aggregation but does not disturb micro-
tubules directly. Proliferating HMEC-1 were treated with 30 or 100 nM ChB for the
indicated time periods, fixed and stained for F-actin (upper panel) or α-tubulin (lower
panel). Arrows indicate actin aggregates. Scale bar represents 20 µm (n=2).
These cells, retracted after Ch treatment, were still viable as propidium iodide staining was
negative, cells recovered to normal cell size after substance removal and nicoletti assay
showed less than 10% nuclear fragmentation (Figure 3.8).
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Figure 3.8: Cells condensated after Chondramide treatment are still viable. A: The
cell membrane of condensated cells is still intact. Chondramide treated HMEC-1 were
stained with propidium iodide (right images). Cells treated with Triton X-100 (TX-100)
served as positive control (PC). B: Condensated HMEC-1 recover after removal of Chon-
dramide. HMEC-1 were treated with ChA for 24 h (left) or ChA was removed after
8 h and incubated for further 16 h without ChA (right). Scale bar represents 20 µm.
C: Less than 10% of HMEC-1 undergo nuclear fragmentation after cellular condensa-
tion. HMEC-1 were treated with indicated concentrations for 48 h, stained with propid-
ium iodide and the percentage of nuclear fragmentation was measured.
Following the aggregation via time lapse imaging using pLifeakt-GFP, we could see that
also at 30 nM Ch aggregates arise from stress fibers after 2 to 4 h and are then transported
proximally to the nucleus (Figure 3.9). This aggregate formation is time and concentration
dependent (data not shown). At the same time, lamellipodia appear to be completely unaf-
fected. Thus, 30 nM Ch leads to an aggregation of stress fibers while lamellipodia remain
still unaffected.
37
3.1 Chondramide diminishes angiogenesis in vitro and in vivo
Figure 3.9: Actin nucleation occurs at stress fibers followed by aggregate transporta-
tion to the perinuclear region. Time lapse imaging of transfected HMEC-1 (pLifeakt-
GFP) treated with 30 nM ChB for indicated time periods was performed. One represen-
tative time serie was chosen out of three independent experiments. Scale bar represents
50 µm.
In order to characterize these aggregates, we stained for markers of aggresomes, which
have previously been described in connection to misfolded proteins and actin binding com-
pounds [59, 60]. Thereby, aggresomes are located in the perinuclear region close to the
microtubule organizing centre (MTOC), are not related to lysosomes or endosomes and in-
clude actin binding proteins in case of actin binding compounds.
Under Ch treatment, 80% of the cells show an aggregate in close proximity to the MTOC
(Figure 3.10).
Figure 3.10: Chondramide induced aggregates are located in proximity to the MTOC.
HMEC-1 were treated with 30 nM ChB, stained for γ-tubulin (green, white arrows) and
counted. Cells were distinguished in two groups: (+) aggregates close to the MTOC or
(-) not. Left: Representative images are shown. Scale bar represents 20 µm. Right: The
number of cells with close proximity of aggregate and MTOC was counted (n=3).
Further, the marker for lysosomal or endosomal compartments, LAMP-1 or Rab5, respec-
tively, were stained to check a possible localization. However, we could see no overlap in-
38
3.1 Chondramide diminishes angiogenesis in vitro and in vivo
dicating neither a lysosomal nor an endosomal localization of the aggregates (Figure 3.11).
Finally, staining of the two actin binding proteins p21-Arc and Cortactin showed a clear
colocalization with the aggregate (Figure 3.11). These findings indicate that Ch induces ag-
gresome formation.
Figure 3.11: F-actin aggregates are neither lysosomal nor endosomal and contain actin
binding proteins. A: HMEC-1 cells were stained via LAMP-1 (green) for lysosomes
or Rab5 (green) for endosomes, respectively. Arrows point to aggregates. B: HMEC-
1 were stained for F-actin (arrows indicate aggregates), nuclei and the actin binding
proteins p21-Arc or Cortactin (green), respectively. The overlap of actin with p21-Arc
or Cortactin, respectively, is shown in yellow. For all stainings, representative images
were chosen out of three independent experiments. Scale bars represent 20 µm.
3.1.5 Chondramide reduces adhesion on collagen and the maturation of focal
adhesions
One major step in migration and maturation of tubes is the attachment to surfaces. Thus,
the influence of Ch on the adhesion of endothelial cells to ECM proteins was tested. On
collagen, a clearly decreased number of cells could adhere when treated with 100 nM Ch,
whereas on fibronectin no change in cell number could be seen (Figure 3.12 A). However,
for both substrates, cells were not able to spread and showed a complete globular form at
100 nM (Figure 3.12 B, C). Additionally, half of the cells adhering on fibronectin showed an
irregular shape meaning disturbed spreading. So, obviously, Ch can reduce on the one hand
adhesion of cells to collagen and on the other hand also affects spreading on both matrices.
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Figure 3.12: Chondramide reduces adhesion on collagen and spreading of endothe-
lial cells. A: HUVECs were pretreated with ChB and seeded on fibronectin or col-
lagen, respectively. After 30 min adhesion, cells were fixed, stained and counted on
four images per sample and experiment (One-way ANOVA, Tukey post-test, * p<0.05,
n=3). B,C: Chondramide treated cells cannot spread after attachment on fibronectin (B)
and collagen G (C). Images were counted for normal spreading cells (normal), irregular
shaped cells, showing non-symmetrical spreading (irregular), and completely rounded
cells (globular), (n=3).
To elucidate this in more detail, we analyzed whether Ch influences integrins. Typical in-
tegrins for both substrates, α5 for fibronectin and α2β1 for collagen, were stained in Ch
treated cells (Figure 3.13). Thereby, 30 nM were chosen as cells at 100 nM did not adhere or
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were completely rounded. We could see for both substrates that cells showed less integrin
stainings at the end of stress fibers (arrows). This indicates that accumulations of integrins
at stress fibers representing mature focal adhesions are reduced in Ch treated cells.
Figure 3.13: Chondramide disturbs the maturation of focal adhesions. Samples were
stained for the fibronectin specific integrin α5 (left) and the collagen specific integrin
α2β1 (right), as well as actin and nuclei. Arrows indicate accumulation of integrins
representing major focal adhesions. Representative images are shown. Bars represent
20 µm (n=3).
3.1.6 Chondramide affects integrin associated signaling by inhibiting Src
activity
Focal adhesions play a major role in migratory signaling. Since these were influenced by Ch,
we analyzed downstream signaling pathways. First, FACS analysis on total and active inte-
grin β1 was performed (Figure 3.14). Both active and inactive integrin β1 were less present
at the cell surface under Ch treatment hinting towards a trafficking problem but not a prob-
lem of integrin activation.
Next, the major downstream complex consisting of FAK and Src was tested on its activity via
the phosphorylation statuses of its components. The autophosphorylation site Y397 of FAK
was unchanged under Ch treatment (Figure 3.15). However, the Src autophosphorylation
at Y416 showed less phosphorylation after incubation with Ch. Finally, the Src-dependent
phosphorylation of the FAK (Y576/577) was tested and showed less phosphorylation after
Ch treatment. These data indicate a reduction in the activity of the Src kinase upon Ch treat-
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ment.
The inhibition of Src using the specific inhibitor Saracatenib reduced the migration of en-
dothelial cells down to 60% at 10 µM (Figure 3.16 A). At the same concentration, the au-
tophosphorylation of Src at Y416 is reduced (Figure 3.16 B) indicating its importance for
migration.
Figure 3.14: Chondramide reduces total and active β1 integrin on the cell surface.
HUVECs were pretreated with ChB (4 h) and harvested for FACS-analysis (One-way
ANOVA, Tukey post-test, * p<0.05, n=3). Conducted by D. Bartel.
Figure 3.15: Chondramide reduces Src activity. HUVECs were pretreated with ChB
(4 h, 30 nM), seeded freshly and harvested for Western blot analysis. Upper panel:
Representative Western blot images are shown. Lower panel: Densitometric analysis
of Western blots. One-way ANOVA, Tukey post-test, * p<0.05, n=3. Conducted by D.
Bartel.
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Figure 3.16: Specific inhibition of Src using Saracatenib reduces migration of HU-
VECs. A: Upper panel: Representative images of scratch assay are shown. The area
covered with cells is displayed in green. Lower panel: Images were analyzed on cell
covered area. (One-way ANOVA, Tukey post-test, * p<0.05, n=3). B: Western blot of
Saracatenib treated HUVECs for pY416-Src and tot-Src are shown. GAPDH serves as
loading control (n=1).
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3.1.7 Chondramide reduces Rho GTPase activity
The FAK/Src complex regulates the activity of the RhoGTPases Rac1 and Rho. To test
whether their activity is reduced by Ch, pull down assays were performed (Figure 3.17).
Both Rac1 and Rho showed reduced activity upon Ch treatment.
Concomitant with that, the downstream target to Rho, MLC2, showed less phosphorylation
at S19 as seen in Western blot and fluorescent staining (Figure 3.18). Thus, targeting the actin
cytoskeleton has an effect on the upstream effectors of active Rac1 and Rho.
Figure 3.17: Chondramide reduces the amount of GTP-bound Rac1 and Rho. HU-
VECs were pretreated with ChB (4 h, 30 nM), seeded freshly and harvested for pull
down assay. Upper panel: Representative Western blot images are shown. Lower panel:
Densitometric analysis of Western blots. One-way ANOVA, Tukey post-test, * p<0.05,
n=3. Rho pull down was conducted by D. Bartel.
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Figure 3.18: Treatment with Chondramide reduces MLC2 phosphorylation. A: West-
ern blot of Ch treated HUVECs (4 h, 30 nM) for pS19-MLC2 and tot-MLC2 are shown.
GAPDH serves as loading control. Left panel: Representative Western blot images are
shown. Right panel: Densitometric analysis of Western blots. One-way ANOVA, Tukey
post-test, * p<0.05, n=3. B: Fluorescent stainings of Ch treated HUVECs are shown.
Cells were stained for F-actin, nuclei and ppT18S19-MLC2 (n=3). Scale bar represents
50 µm. Conducted by D.Bartel.
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3.1.8 Chondramide diminishes angiogenesis in vivo
Finally, the in vivo effect of Ch on tumor vasculature was evaluated. In a murine xenograft
tumor model with MDA-MB-231 cells, Ch treatment led to a significantly reduced tumor
weight [61]. These tumors were used to analyze the degree in vascularization of treated
and untreated tumors. Stainings of tumors for CD31 revealed a significant reduction of the
microvessel density in Ch treated tumors (Figure 3.19).
Figure 3.19: Chondramide reduces tumor angiogenesis in vivo. 10 mice per group with
subcutane tumors were treated thrice a week with Chondramide or solvent i.p. for 34
days. Harvested tumors were stained for CD31 (left panel). Four images per tumor (10x
objective) were taken and vessels were counted. (40 images per group, t-test, unpaired,
* p<0.05).
46
3.2 Chondramide inhibits metastasis in vitro and in vivo
3.2 Chondramide inhibits metastasis in vitro and in vivo
3.2.1 Chondramide diminishes metastasis in vivo
First, we evaluated the pharmacological, anti-metastatic potential of Chondramide (Ch) in
vivo. To this end, a 4T1-Luc metastatic mouse breast cancer model was used [62, 63, 64].
Hereby, a murine 4T1-Luc mammary cancer cell line expressing recombinant luciferase is
injected intravenously in BALB/cBγJRj mice. These luciferase expressing cancer cells metas-
tasize to the lung and can be detected via bioluminescent measurement. Experiments were
conducted by L. Schreiner [65] and R. Kubisch.
The evaluation of the bioluminescent signal in the lungs of untreated and Ch treated mice
revealed a significant reduction of metastasis for Ch treated mice compared to control mice
(Figure 3.20 A, B). Over the treatment period, the weight of Ch treated mice stayed constant
indicating a good tolerance of 0.5 mg/kg Ch during application (Figure 3.20 C).
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Figure 3.20: Chondramide reduces metastasis in vivo. 1 x 105 4T1-Luc cells were
injected intravenously into pretreated (0.5 mg/kg ChB) and untreated BALB/cBγJRj
mice. A: 8 days after cell inoculation mice were sacrificed, lungs harvested and used
for recording bioluminescence signals. Each lung was imaged from the dorsal (upper
panel) and ventral (lower panel) side. Color bar scales were equalized. B: Quantitative
evaluation of metastasis to the lungs. Regions of interest were defined (ROI) and total
luciferin signal in ROIs was calculated as photons/second/cm2 (total flux/area). Bars
represent the mean ± SEM of ten lungs per group. * p<0.05 (t-test). C: Mouse weight
over treatment period. Weight of treated (ChB) and untreated (DMSO) from day of cell
inoculation (day 0) to euthanasia (day 8) is shown as the mean ± SEM for each group.
Conducted by L. Schreiner [65] and R. Kubisch.
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3.2.2 Chondramide reduces migration of highly invasive cancer cells
Based on this promising result, the activity of Ch on cancer cell metastasis was evaluated in
vitro. In a first trial, the effect of Ch on cancer cell migration was tested with several cancer
cell lines. To this end, the cell lines MCF-7 and L3.6pl as well the cell lines HUH-7 and
MDA-MB-231 were tested in scratch-assay. The migration of MCF-7 and L3.6pl cells was
only reduced at 200 nM ChA. In contrast, the migration of the more invasive cells HUH-7
was inhibited to 70 or 50% at 50 or 200 nM Ch, respectively, and the highly invasive cell line
MDA-MB-231 was inhibited in a concentration dependent manner up to less than 50% at
200 nM (Figure 3.21). As a model for highly invasive cancer cells the cell line MDA-MB-231
was used for further experiments.
Figure 3.21: Chondramide inhibits cell migration of several cancer cell lines. Can-
cer cells were allowed to migrate in scratch assay at indicated concentrations of Chon-
dramide (n=3).
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3.2.3 Chondramide inhibits FCS induced migration and invasion in vitro
Next, the inhibitory effect on FCS induced migration was tested. For this purpose, MDA-
MB-231 were tested in Boyden chamber assay. The migration could be inhibited significantly
by Ch at 30 or 100 nM down to 60 or 70%, respectively (Figure 3.22 A). To study the effect
of Ch on invasiveness, matrigel filled Boyden chambers were used. Here, Ch inhibited cell
invasion at 30 nM and 100 nM to less than 50% (Figure 3.22 B).
Figure 3.22: Treatment with Chondramide reduces breast cancer cell migration and
invasion. A: Chondramide treated and untreated MDA-MB-231 cells were allowed to
migrate in Boyden chamber for 16 h. B: Chondramide inhibits invasion of MDA-MB-
231 cells through matrigel in Boyden chamber (48 h). A,B: For positive control (PC)
lower compartment was filled with medium plus 10% FCS, for negative control (NC)
only medium without FCS was added. Bars indicate migration relative to PC. * p<0.05
One-way ANOVA,Tukey post-test, n=3.
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3.2.4 Chondramide reduces adhesion of MDA-MB-231 cells on several surfaces
In order to further elucidate the effect of Ch on cell migration, the important step in migra-
tion, cell adhesion, was tested. Here, Ch reduced the attachment of cells to several matrices
at 100 nM, however, not at 30 nM (Figure 3.23 A). This indicates, that anti-adhesive proper-
ties of Ch can contribute to an anti-migratory effect, however, this seems not to be the only
factor diminishing cancer cell migration. Fluorescent stainings of the adhering cells revealed
that cells treated with 30 nM Ch showed normal cell morphology whereas the few adhering
cells at 100 nM Ch were not able to spread (Figure 3.23 B).
Figure 3.23: Chondramide inhibits adhesion and spreading of MDA-MB-231 cells. A:
Pretreated MDA-MB-231 cells were seeded freshly on different surfaces and counted
after fixation. * p<0.05 One-way ANOVA, Tukey post-test, n=3. B: Cells from A were
stained for F-actin, nuclei and Vinculin. Bar represents 50 µm.
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3.2.5 Chondramide affects stress fibers of MDA-MB-231 cells
To get a first insight into the intracellular processes upon Ch treatment, the actin cytoskele-
ton of MDA-MB-231 cells was stained. Thereby, we observed thinner stress fibers compared
to control and aggregation close to the nucleus after 4 and 8 h (Figure 3.24 A). After 24 h
the cells were completely condensed. These condensed cells recovered to total cell size after
substance removal like endothelial cells indicating their viability (Figure 3.24 B).
Figure 3.24: Chondramide leads to reduction of stress fibers and F-actin aggregation.
A: MDA-MB-231 cells were treated with 200 nM ChA or DMSO for indicated time pe-
riods, fixed and stained for F-actin and nuclei. B: Removal of Ch allows cells to recover
to normal cell size. Bar represents 20 µm.
3.2.6 Chondramide reduces the activity of the RhoGTPase Rho but not Rac1
To investigate whether stress fiber reduction seen in figure 3.24 is a direct effect of Ch or in-
duced due to alterations in signaling, the upstream effectors of the actin-cytoskeleton were
tested on their activity. Therefore, the RhoGTPases Rac1 and Rho were analyzed using
pull down assay. Hereby, we could see no alterations in the amount of GTP-bound Rac1
(Figure 3.25 A). However, the level of GTP-bound Rho was clearly reduced at 30 nM Ch
(Figure 3.25 B). The reduced activity of Rho could be confirmed further downstream as the
regulatory myosin light chain 2 (MLC2) was less phosphorylated at Ser19 (Figure 3.25 C).
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Figure 3.25: Chondramide affects activation of the RhoGTPase Rho. A: Rac1 pull
down was performed for untreated and ChB treated cells upon EGF stimulation (5 min).
B: After same treatment a Rho pull down was conducted. C: Myosin light chain 2
(MLC2) was analyzed on its activation state via Western blot analysis upon EGF stimu-
lation (5 min). Bars represent mean± SEM. * p<0.05 One-way ANOVA, Tukey post-test,
n=3. A,B,C: Left panel: One representative Western blot is shown. Right panel: Densit-
ometric analysis of Western blots.
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3.2.7 Chondramide has no effect on the activation of the EGF-receptor and
downstream signaling
Further, the reason for the reduced Rho activity should be evaluated. As the RhoGTPases
were activated through extracellular EGF stimulation in these experiments, we tested the
EGF-receptor (EGFR) on its ability for autophosphorylation. The autophosphorylation at
Y1068 of the EGFR was not affected by Ch treatment (Figure 3.26). Neither 30 or 100 nM
Ch nor a very short or longer time point showed any changes in the phosphorylation state.
Concomitant with that, the phosphorylation status of the downstream effectors to EGFR,
Akt and Erk, at S473 or T202/Y204, respectively, showed no effect of Ch treatment compared
to positive control (Figure 3.26). This data indicates normal activation of these pathways
under Ch treatment.
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Figure 3.26: Chondramide does not influence EGFR signaling. MDA-MB-231 cells
were treated with Ch (1 or 24 h), stimulated with EGF (5 min) and analyzed via Western
blot analysis on EGFR, Akt and Erk. Left panel: One representative Western blot is
shown. Right: Densitometric analysis of Western blots. * p<0.05 One-way ANOVA,
Tukey post-test, n=3.
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3.2.8 Chondramide diminishes cellular contractility
The activation of the RhoGTPase Rho can also occur due to intra- or extracellular forces.
One guanine nucleotide exchange factor (GEF) that is known to be activated by force and to
activate RhoA in MDA-MB-231 cells is Vav2. In fact, the activity dependent phosphoryla-
tion site Y172 of Vav2 was less phosphorylated under Ch treatment (Figure 3.27).
To finally see whether cellular force is reduced under Ch treatment, we tested the ability of
MDA-MB-231 cells to exert contractile force. Cellular force on surrounding matrix can be
visualized as exerted forces result in matrix movement which can be imaged by embedded
fluorescent beads [66, 56]. To this end, cells were embedded in matrigel containing fluores-
cent beads and images were taken over 4 h. Control cells revealed a clear contractile force
on the surrounding matrix as seen by bead movement towards the cell (Figure 3.28 A). This
bead movement was reduced at 30 nM and even more at 100 nM (Figure 3.28 B). This data
indicates a significant reduction of intracellular originating force in cells treated with Ch.
Figure 3.27: Phosphorylation of the Rho-GEF Vav2 is reduced by Chondramide. Phos-
phorylation of Vav2 at Y172 was tested via Western blot analysis upon EGF stimulation.
Left panel: One representative Western blot is shown. Right: Densitometric analysis of
Western blots. (n=3)
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Figure 3.28: Chondramide diminishes cellular contractility. A: MDA-MB-231 cells
were pretreated for 24 h as indicated, stained with CellTrackerTMRed, embedded in
matrigel containing fluorescent beads and pictures were taken over 4 h every 15 min.
Cellular, contractile force on the surrounding matrix was visualized via bead movement
towards the cell and analyzed using PIV analysis. Upper panel: Representative images
of cells (red) and fluorescent beads (green) t=0. Lower panel: PIV analysis of bead ve-
locity in the 2D projection. Color codes show bead velocity indicating applied force.
Direction of vectors indicates averaged direction of bead movement. B: For quantitative
analysis the radial velocity (bead velocity towards the cell center) per data point was




The cytoskeleton is an attractive target in cancer therapy as proven by the treatment of
cancer with microtubule disturbing drugs. In the evaluation of actin binding compounds
performed in the 70s and 80s, targeting the actin cytoskeleton was assessed as too toxic for
clinical application [67, 9, 10]. However, since then, new actin binding compounds were dis-
covered, that could reveal different properties to those first tested, and new possibilities are
established for directed targeting of chemical compounds to their site of action. These de-
velopments rise the interest in actin targeting compounds in cancer treatment again. Never-
theless, functional and mechanistic studies concerning cancer treatment with actin targeting
compounds are rare now due to their negation in the last centuries. Especially, oncogenic
processes dependent on the actin cytoskeleton are worthwhile to test [68]. Thus, the migra-
tion dependent processes, tumor angiogenesis or tumor metastasis, are attractive to target
with an actin binding compound.
4.1 Chondramide as anti-angiogenic agent
4.1.1 Actin targeting in anti-angiogenic therapy
Regarding angiogenesis, investigations targeting the actin cytoskeleton directly to inhibit
the process of blood vessel formation are relatively rare. Among them, the actin destabilizer
Cytochalasin D was shown in vitro to inhibit cell growth, migration and tube formation
[69] of endothelial cells as well as to diminish angiogenesis in a chorioallantoic membrane
(CAM) assay [70]. For Latrunculin, its derivative 15-O-methyllatrunculin B showed promis-
ing anti-angiogenic activity in a CAM assay [71]. To our knowledge, the actin nucleating
compound Jasplakinolide has never been tested for potential anti-angiogenic effects pos-
sibly due to high toxicity in vivo [10, 72]. Thus, actin binding compounds have not been
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investigated in detail concerning their mechanism of action and potency in angiogenic ther-
apy.
This study shows promising anti-angiogenic effects of Chondramide in vitro and in vivo.
In fact, we could show a pharmacological reduction of tumor blood vessels in vivo at a
non-toxic concentration. Furthermore, we could demonstrate that major hallmarks of an-
giogenesis [29], namely the proliferation, the migration and the in vitro tube formation of
endothelial cells, are inhibited by Chondramide in a low nanomolar range.
4.1.2 Chondramide induces aggresome formation
Intracellularly, the most obvious effect of Chondramide in endothelial cells potentially caus-
ing the anti-migratory effect is the aggregation of fibrilous actin. This observation is in line
with another study applying Chondramide in Pt K2 potoroo cells [26] and is also known for
other actin binding substances [60]. These actin toxin induced lumps are called aggresomes,
a cellular stress response to missfolded proteins [59]. Criteria for aggresomes are the locali-
sation close to the MTOC and for actin toxins the inclusion of actin binding proteins [73, 74].
These features are shared with the Chondramide induced aggregates revealing those as ag-
gresomes. Thus, Chondramide induces aggresomes as a stress response in endothelial cells.
4.1.3 Chondramide reduces stress fibers potentially diminishing focal adhesion
maturation
The aggregation of actin by Chondramide is first seen at stress fibers and results in a disin-
tegration of these fibres. This is in accordance with findings for Jasplakinolide [74] as well
as fluorescently labeled Chondramide which preferentially stained stress fibers [27]. The
functionality of stress fibers, however, is important for further structures in the cell. So,
functional contractility from stress fibers is needed for the maturation of focal adhesions in
endothelial cells [75]. Thus, we propose the disintegration of stress fibers as the reason for
impaired maturation of focal adhesions observed after Chondramide treatment. In addition
to this, the reduced amount of integrins at the cell surface may contribute to fewer focal
adhesions.
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4.1.4 Chondramide diminishes signal transduction at focal adhesions and
downstream signaling
Focal adhesions represent a major platform for integrin outside-in signaling, which is im-
portant in spreading and migration [45]. Consequently, the disturbance of these adhesive
structures has a striking impact on important signaling pathways for migration. One central
complex in this signaling cascade is built by the focal adhesion kinase (FAK) and Src. Under
Chondramide treatment, the autophosphorylation of Src at Y416, needed for its own acti-
vation [76], and the Src dependent phosphorylation of FAK at Y576/577 [77] are reduced.
Both phosphorylation sites are an indication of reduced Src activity. Interestingly, it has
been reported that the translocation of Src to focal adhesions is actin dependent in swiss
3T3 cells [78, 79]. Thus, in addition to a reduced activation of Src due to less integrins, the
translocation to the membrane and FAK could be impaired resulting in a reduced autophos-
phorylation. This could also explain why the autophosphorylation of Src but not the one
of FAK is disturbed. Most importantly, the inhibition of Src yielded in reduced migration
of endothelial cells. This Src dependent inhibition reveals the importance of Src activity for
endothelial cell migration.
Corresponding to a reduced activity of Src and, thus, the whole complex FAK/Src, further
downstream signaling would be expected to be diminished [45]. Indeed, the downstream
activated RhoGTPase Rac1 is reduced in activity at same conditions like Src. Although the
FAK/Src complex mediates a transient inhibition of Rho activity, a later Src-dependent Rho
activation is discussed [45]. This activation of Rho is supposed to initiate after the spreading
phase due to mechanical stimuli and could be reduced under Chondramide treatment as
Chondramide treated cells showed defects in spreading, and finally, lead to the lower levels
in Rho-GTP. Obviously, Chondramide has an overall inhibitory effect on the RhoGTPases
and thus, on very important pro-migratory signals.
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4.1.5 Conclusion concerning angiogenesis
Taken together, Chondramide inhibits major pro-migratory signals via the disintegration of
stress fibers, and thus, inhibits migration via two parallel ways: first, the disintegration of
stress fibers itself and second, the resulting reduction in pro-migratory signals like Src and
RhoGTPases (Figure 4.1).
Figure 4.1: Inhibitory effect of Chondramide in endothelial cells. Chondramide induces
actin aggregation and stress fiber solvation. As a consequence, the maturation of focal adhe-
sion is hampered resulting in diminished complex formation of Src and FAK, finally, leading to
reduced activation of RhoGTPases. Concluding, stress fiber solvation, inhibited focal adhesion
maturation and RhoGTPase activity can lead to reduced cell motility, finally, inhibiting angio-
genesis.
With these investigations, we show insights into the mechanism how Chondramide dimin-
ishes the migration of endothelial cells. Further, we can demonstrate that the actin polymer-
izing compound Chondramide inhibits angiogenesis in vitro and in vivo. This work fills the
gap of an actin polymerizing compound for anti-angiogenic therapy. Most importantly, it
supports the idea of targeting actin in anti-angiogenic therapies and reveals Chondramide
as an interesting structure for further development.
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4.2 Chondramide as anti-metastatic compound
The formation of metastasis is the major cause of death in cancer diseases [31]. However,
treatments targeting invasive cells are missing. With Chondramide we tested the anti-
metastatic potential of an actin targeting agent against invasive breast cancer cells.
4.2.1 Chondramide impairs cellular contractility in amoeboid cell migration
During invasion, cellular contractility is of utmost importance. Classic migration depends
on contractility as the cell rear has to be retracted after cell protrusion and formation of new
adhesions in the migration direction. Further, the amoeboid migration of cancer cells is
mostly driven by contractile force depending on Rho/ROCK signaling but not proteolysis
[35, 36]. The highly invasive cell line MDA-MB-231 follows the scheme of an amoeboid
migration through matrigel, requiring a contractile uropod dependent on RhoA and MLC-2
activity [56]. Thereby, cells exert contractile force to the surrounding matrix resulting in
matrix accumulation at the cell rear pushing the cell forward. Accordingly, we observed
an amoeboid cell migration with round cell shape of MDA-MB-231 cells in matrigel and
a matrix deformation shown by fluorescent bead movement. This bead displacement was
abolished after Chondramide treatment indicating reduced contractile force of the cell. The
invasion of MDA-MB-231 cells was inhibited under Chondramide treatment in a compa-
rable setting like contractility indicating that impaired contractility most likely contributes
to reduced invasion. Further, the observation that migration and invasion are inhibited
at same concentrations of Chondramide is reasonable for amoeboid migration considering
that this migration mode is independent of proteolysis but mainly driven by contractile
force.
A reason for the reduced contractility could be the thinning of stress fibers after Chon-
dramide treatment. As stress fibers were thinned in 2D and fluorescent Chondramide was
shown to bind preferentially to stress fibers [27], Chondramide binding to those could affect
their structure, finally, leading to reduced contractility.
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4.2.2 Chondramide impairs pro-contractile signaling
Further, the signaling cascade leading to contractility, via Rho/ROCK and myosin, is known
to enhance invasion when upregulated [80, 81]. Chondramide treatment diminishes the
activity of Rho and MLC2. Other factors like Rac1 or EGFR and its downstream factors,
Akt and Erk, were not affected at same conditions. Thus, Chondramide inhibits the pro-
contractile signaling cascade quite specific.
Concerning the inhibition of Rho, a link to Chondramide is less obvious. Interestingly, a
connection between contractile force and RhoA activation is reported not only from Rho
being required for contractility but also the other way around that contractile force induces
RhoA activation [48]. In this context, Vav2 has been shown to be induced by applied forces
in the form of stretching in mesangial cells [47] and Vav2 is known to be necessary for a full
activation of RhoA in MDA-MB-231 cells [82]. These observations are in line with our find-
ings revealing that Vav2 and RhoA are less active in Chondramide treated cells potentially
reducing contractility (Figure 4.2).
4.2.3 Chondramide shows anti-metastatic effects without acute toxicity
The approach to target the actin cytoskeleton has been thought to be too toxic for clinical
application [10]. However, the feasibility to target actin is shown here in an in vivo mouse
model of tumor metastasis. Herein, treatment with Chondramide diminishes the metastasis
of mammary cancer cells to the lung significantly. As migration is reduced at lower con-
centrations and shorter time points than nuclear fragmentation occurs, we propose that the
inhibitory effect on metastasis is not due to an apoptotic effect but the abrogation of migra-
tion and invasion. The dose of 0.5 mg/kg was well tolerated as the body weight of treated
mice stayed constant throughout the observation period. Although there is still room for
further development, e.g. specific targeting, we could show a pharmacological effect for
Chondramide on metastasis in vivo without acute toxicity.
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4.2.4 Conclusion concerning metastasis
Concluding, Chondramide most likely reduces contractility in two ways: first, via direct
interaction with stress fibers and, second, via reduced intra-cellular force diminishing Rho
activation.
Figure 4.2: Inhibitory effect of Chondramide in breast cancer cells. Chondramide treatment
induces the aggregation of stress fibers and diminishes cellular contractility. Consequently, the
force induced GEF Vav2 as well as the downstream RhoGTPase Rho are less active further re-
ducing contractility.
As therapies against cancer metastasis are still missing, more efforts need to be made in
research addressing metastatic cancer cells. This work provides evidence that actin is a suit-
able target to inhibit cancer cell migration, and gives first insights into underlying mecha-
nisms. Combining actin binding natural compounds with specific targeting strategies could
lead to a powerful weapon to treat tumor metastasis.
4.3 Chondramide as a dual inhibitor of angiogenesis and
metastasis
In the last century, the treatment of cancer with anti-angiogenic drugs faced the problem of
limited success in clinical studies. After a initial response, tumor progression escaped from
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treatment. This led to a survival benefit in the range of month but no change in the overall
survival or permanent cure [83, 84, 85, 86]. Tumor escape is attributed to the establishment
of resistances against anti-angiogenic therapies. One mode of response is the turning-on
of alternative pro-angiogenic pathways when blocking one of those. E.g. in the treatment
with Bevacizumab, a VEGF binding antibody, other angiogenic factors like EGF or platelet
derived growth factor (PDGF) become upregulated [87, 88, 89]
Another mechanism of escape is the selection of aggressive cells due to hypoxic pressure [86,
90]. Via the inhibition of new blood vessel formation, reduced oxygen supply deteriorates
the cellular situation in the tumor favoring motile cells able to escape this environment.
In mouse models as well as in the clinic, the treatment with Bevacizumab increased the
invasiveness of primary tumors [91, 92]. Also the VEGF-receptor tyrosine kinase inhibitor
sunitinib induced invasiveness and metastasis [93].
In this context, the treatment with Chondramide offers a huge advantage. As we could show
with our work that Chondramide interferes with both, angiogenesis and metastasis, the
major side effect of pro-invasive selection could be overcome in one with the anti-angiogenic
therapy.
4.4 Future perspectives
4.4.1 Treatment of anti-angiogenic resistant tumors
Although the treatment of tumors with anti-angiogenic therapies reveals clinical benefits,
possible resistances or escape mechanisms ask for new solutions. In contrast to existing anti-
angiogenic strategies, Chondramide inhibits angiogenesis via stress fiber solvation and the
reduction of pro-migratory signaling cascades. This approach represents a broader strategy
than established therapies targeting the VEGF signaling pathway and tackles a complete dif-
ferent target. Concluding, Chondramide might be effective where other treatments evoked
resistances. To test this hypothesis, cell lines like the murine colon carcinoma cell line CT26,
lymphoma EL4 or lewis lung carcinoma, that showed resistances over anti-VEGF therapies
[94, 95], could be tested with regard to the anti-angiogenic potenial of Chondramide treat-
ment in these systems.
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4.4.2 Targeting both invasive migration modes to inhibit metastasis
Concerning metastasis, in the experimental setting tested in this work MDA-MB-231 cells
show an amoeboid migration mode which can be inhibited with Chondramide. Other work
shows that MDA-MB-231 cells are capable of migrating in a mesenchymal mode when em-
bedded in collagen instead of matrigel [36]. However, when treated with protease inhibitors
cells switch from the mesenchymal, Rac1 and protease dependent mode to the amoeboid
mode which is protease independent [36]. This transition hampers the efficacy of protease
inhibitors in the treatment of metastasis. Thus, protease inhibitors and Chondramide repre-
sent two classes of inhibitors interfering with opposing modes of invasion. Concluding, the
combination of both would be interesting to examine whether invasion would be blocked
completely or cells find another way to escape. Therefore, both migration modes could be
tested in vitro in 3D matrices with single compared to combined application and in vivo
metastasis could be investigated on combination therapy.
4.4.3 Improvement of tissue selectivity
Further, it did not escape our notice, that the approach of targeting the actin cytoskeleton re-
quires special attention concerning tissue selectivity. The in vivo studies showed that there is
a pharmacologically active window large enough for treating tumor angiogenesis or metas-
tasis without acute toxicity in mice models. Still, for further development of Chondramide,
this window would need further enlargement. This could be implemented by encapsu-
lating or targeting the compound. E.g. Cytochalasin D was encapsulated in polyethylene
liposomes which specifically accumulated in tumor tissue and inhibited tumor angiogene-
sis more effective than normal Cytochalasin D [96]. A similar approach would be possible
for Chondramide which could be facilitated in collaboration with Prof. Dr. Ernst Wagner
working on PEGylation drug delivery systems. Thereby, Chondramide could be encapsu-
lated, tested in vitro on cell toxicity and functionality and, finally, in vivo studies should be
performed investigating the effect on tumor growth and vascularization.
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5: Summary
Tumor angiogenesis and cancer metastasis are crucial processes contributing to the progres-
sion of cancer. Both processes are based on cellular migration which involves high plasticity
of the actin cytoskeleton. In the last centuries, actin targeting was thought to be too toxic,
however, new actin binding substances are found and targeting strategies are further de-
veloped rising the interest in actin targeting again. Chondramide represents a new actin
targeting compound that has not been tested for its suitability for cancer treatment so far.
Isolated from the myxobacterium Chondromyces crocatus, Chondramides bind and polymer-
ize actin in eukaryotic cells.
In this work, Chondramide was tested on its potency to inhibit angiogenesis and tumor
metastasis. Further, the corresponding actin structures and pro-migratory signaling were
analyzed to investigate the consequences of the actin binding compound.
In fact, we show that Chondramide inhibits major angiogenic processes such as endothelial
cell proliferation, migration and tube formation in a lower nanomolar range. Intracellu-
larly, Chondramide leads to an actin aggregation at stress fibers and reduces maturation of
focal adhesions. At this signaling platform, the activation of Src is diminished under Chon-
dramide treatment with the consequence of reduced RhoGTPase activation, thus, downreg-
ulating pro-migratory signals.
Concerning metastasis, Chondramide inhibits migration and invasion of the invasive cancer
cell line MDA-MB-231 at nanomolar concentrations. We show that Chondramide abolishes
the contractility of the cell which is achieved via two ways: first, an aggregation of stress
fibers and, second, a force dependent negative feedback loop via Vav2 and Rho.
In vivo, Chondramide reduced the microvessel density in Chondramide treated tumors and
the metastasis of cancer cells to the lung revealing a pharmacological active window with-
out acute toxicity in two animal models.
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Concluding, this work provides evidence for the feasibility of targeting actin with Chon-
dramide to inhibit tumor angiogenesis and metastasis and gives first insights in the under-
lying intracellular processes in endothelial and metastatic cells. This work gives the basis
for further development of actin binding compounds in low dose combination therapies or
with specific targeting to treat tumor angiogenesis and metastasis.
Figure 5.1: Chondramide shows anti-angiogenic and anti-metastatic potency. In en-
dothelial cells, Chondramide induces stress fiber aggregation and inhibits the matura-
tion of focal adhesions leading to reduced activity of Src as well as downstream Rho-
GTPases Rac1 and Rho, thus, resulting in reduced angiogenesis. In invasive cancer cells,
Chondramide reduces cellular contractility via stress fiber aggregation and dimished
Rho activity, finally, reducing cancer cell metastasis.
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Table 6.1: List of abbreviations
Abbreviation Full name




DMEM Dulbecco’s Modified Eagle Medium
DMSO Dimethylsulfoxide
EC Endothelial cell




EGTA Ethylene glycol tetraacetic acid
EGF Epidermal growth factor
EGF-R Epidermal growth factor receptor
FACS Fluorescence activated cell sorter
F-actin Fibrilous actin
FAK Focal adhesion kinase
FCS Fetal calf serum
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
GEF Guanine nucleotide exchange factor
HMEC Human microvascular endothelial cell
HUVEC Human umbilical vein endothelial cell
Jk Jasplakinolide
MLC Myosin light chain
MTOC Microtubule organizing center
PBS Phosphate buffered saline
PDGF Platelet derived growth factor
p-FA Para-formaldehyde
PIV Particle image velocimetry
PMSF Phenylmethylsulfonyl fluoride
SDS Sodium dodecyl sulfate
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